茵花品牌怎么样申请店铺

我要投票

茵花在女性洗液行业中的票数：253 更新时间：2025-04-27

茵花是哪个国家的品牌？「茵花」是重庆希尔安药业有限公司旗下著名品牌。该品牌发源于重庆市，由创始人唐董在1994年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力茵花品牌出海！通过在本页面挂载茵花品牌的产品链接和联系方式，可以提高茵花产品曝光！跨境电商爆单神器，目前只要100元/年哦~

重庆希尔安药业有限公司，茵花洗液，女性洗液知名品牌，重庆市著名商标，集研发、生产、销售中药材种植/中药饮片加工为一体高新技术企业

希尔安药业起源于公元1698年的“伍舒芳草堂”，承袭“重庆中药总厂”之制药精髓，至今已有300多年的历史。公司始终秉持“德布天下，药济苍生”的企业理念，树百年商誉”为企业目标，如今已经发展成一家集研发、生产、销售于一体的综合性制药企业。

希尔安药业位于重庆市合川工业园区，总资产12.5亿元，占地面积330亩，Ⅰ期工程总建筑面积为76207m2，总投资达6亿元；颗粒剂、胶囊剂、片剂等15个剂型通过2010年版GMP认证，年产值将达到50亿元。新生产基地实现厂房标准化、生产过程自动化、环境保护科学化。

公司产品资源丰富,拥有生产批文166个，其中71个品种列入《国家基本医疗保险药品目录》；22个品种列入《国家基本药物目录》；12个中药保护品种，2个优质优价品种。

公司旗下两大商业机构：希尔安药品销售公司；希尔安康泽医药连锁有限公司；四大营销机构：处方药营销中心、OTC营销中心、普药营销中心、新医疗营销中心；实施“广覆盖、深耕作”营销战略，销售网络覆盖全国31个省、自治区、直辖市以及东南亚、欧洲、美洲等部分海外市场，形成从省会城市综合医院到区县以及乡镇卫生院、个体诊所、零售药房深度耕作的销售格局，致力于打造骨科、儿科、肿瘤科、皮肤科等多条具有竞争优势的产品线，实现每年销售额增长50%以上的目标。

公司下属两家研发机构：重庆思科药物研究所有限公司，专注于化药、中药及天然药物、大健康产品的开发；重庆科润生物医药研发有限公司，专注于生物制剂研发；拥有重庆市博士后科研工作站、重庆市企业技术中心、重庆市中药制剂工艺工程技术研究中心等多个市级技术创新平台。公司始终以“科技”为手段，坚持“仿创结合、药物与大健康产品研发并重”的方针，形成“筛选一批、研发一批、储备一批”的研发格局。

为了适应国家不断推进的医疗卫生体制改革以及新的经济形势，公司大力实施人才战略、品牌战略、创新战略；传承三百年伍舒芳中药文化精髓，构建以“德布天下，药济苍生”为核心的企业文化体系；打造市场准入和市场营销两大核心竞争力，实现颠覆式发展，力争在未来6～8年内，将希尔安打造成百亿级医药企业。

Chongqing hilan Pharmaceutical Co., Ltd., a famous brand of Yinhua lotion, women's lotion and Chongqing famous trademark, is a high-tech enterprise integrating R & D, production and sales of Chinese herbal medicine planting / processing of Chinese herbal pieces. Hilan pharmaceutical industry originated from wushufang thatched cottage in 1698 A.D., inherits the pharmaceutical essence of Chongqing general herbal medicine factory, and has a history of more than 300 years. The company always adheres to the enterprise concept of "debuxia, medicine for the people" and the enterprise goal of "building a hundred years' goodwill". Now it has developed into a comprehensive pharmaceutical enterprise integrating research and development, production and sales. Hilan pharmaceutical is located in Hechuan Industrial Park, Chongqing, with a total asset of 1.25 billion yuan, covering an area of 330 mu. The total construction area of phase I project is 76207m2, with a total investment of 600 million yuan. 15 dosage forms such as granules, capsules and tablets have passed GMP certification in 2010, with an annual output value of 5 billion yuan. The new production base realizes factory standardization, production process automation and environmental protection scientization. The company has rich product resources, with 166 production approvals, 71 of which are listed in the national basic medical insurance drug catalog; 22 of which are listed in the national basic drug catalog; 12 of which are protected by traditional Chinese medicine, and 2 of which are of high quality and high price. The company's two major commercial organizations: hilan pharmaceutical sales company; hilan Kangze pharmaceutical chain Co., Ltd.; four major marketing organizations: prescription drug marketing center, OTC marketing center, general drug marketing center, new medical marketing center; the implementation of the "wide coverage, deep cultivation" marketing strategy, the sales network covers 31 provinces, autonomous regions, municipalities directly under the central government, as well as Southeast Asia, Europe, the United States Some overseas markets, such as Zhouzhou, have formed a sales pattern of deep cultivation from provincial capital city general hospitals to district and county health centers, individual clinics and retail pharmacies. They are committed to building multiple product lines with competitive advantages, such as orthopedics, pediatrics, oncology and dermatology, to achieve the goal of increasing sales by more than 50% every year. Two R & D institutions under the company: Chongqing Cisco Pharmaceutical Research Institute Co., Ltd., which focuses on the development of chemical medicine, traditional Chinese medicine, natural medicine and large health products; Chongqing Kerun biomedical research and Development Co., Ltd., which focuses on the research and development of biological agents; Chongqing postdoctoral research station, Chongqing enterprise technology center, Chongqing Traditional Chinese medicine preparation process engineering technology research center, etc Municipal technology innovation platforms. The company always takes "science and technology" as a means, adheres to the policy of "combination of imitation and innovation, equal emphasis on research and development of drugs and large health products", and forms a research and development pattern of "selecting a batch, researching and developing a batch, and reserving a batch". In order to adapt to the constantly advancing medical and health system reform and the new economic situation, the company vigorously implements the talent strategy, brand strategy and innovation strategy; inherits the essence of Wu Shufang's traditional Chinese medicine culture for three hundred years, constructs the enterprise culture system with the core of "debriefing the world, medicine saving the people"; creates the two core competitiveness of market access and marketing, and realizes the subversive development, Strive to build hilan into a 10 billion level pharmaceutical enterprise in the next 6-8 years.

本文链接： https://brand.waitui.com/7094bf05f.html 联系电话：请联系客服添加联系邮箱：请联系客服添加